Bolt Biotherapeutics (NASDAQ:BOLT) Releases Earnings Results, Meets Estimates

Bolt Biotherapeutics (NASDAQ:BOLT) released its quarterly earnings results on Monday. The company reported ($0.38) EPS for the quarter, meeting the consensus estimate of ($0.38), Zacks reports. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT traded down $0.00 on Monday, reaching $0.44. The company’s stock had a trading volume of 97,537 shares, compared to its average volume of 169,988. Bolt Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.56. The stock has a market capitalization of $16.75 million, a P/E ratio of -0.26 and a beta of 0.94. The stock’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.